Full TitleEvaluation of Ruxolitinib and Thalidomide Combination as a Therapy for Patients with Myelofibrosis
Myelofibrosis is a disease of the bone marrow. Ruxolitinib is a drug used to treat myelofibrosis that works by inhibiting an abnormal form of a protein called Jak. In this study, researchers are assessing the addition of the drug thalidomide to ruxolitinib treatment in people with myelofibrosis, to see if this combination reduces symptoms as well as the need for blood transfusions. Thalidomide is already used to treat other blood diseases, such as multiple myeloma.
Patients who have not previously taken ruxolitinib will take that drug alone for 3 months before taking thalidomide as well. Both ruxolitinib and thalidomide are taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have myelofibrosis that requires treatment.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Raajit Rampal at 212-639-2194.